Understanding Biosimilars: The Science, Manufacturing, and Safety of Biological Therapeutics

Biopharmaceuticals have transformed modern medicine, offering targeted treatments for complex conditions such as cancer, autoimmune disorders, and diabetes. As patents on original biological drugs expire, a specialized category of therapeutics called biosimilars has emerged to improve healthcare access globally.

According to the World Health Organization (WHO), a biosimilar is a biological medicine that is highly similar in quality, safety, and efficacy to an already approved reference biological product (the “reference product”).

Why Biosimilars Are Not Generic Drugs

A frequent point of confusion is equating biosimilars with generic medicines. While both provide cost-effective alternatives after patent expiration, their manufacturing science and molecular nature are fundamental differences:

• Chemical Synthesis vs. Living Systems: Generic drugs are created through predictable chemical synthesis, resulting in identical molecular structures. Biosimilars are derived from living organisms (host cells such as bacteria, yeast, or mammalian cell lines), making exact duplication impossible.
• Structural Size and Complexity: Small-molecule chemical drugs consist of simple, well-defined molecular structures (~100–500 Daltons). Biological therapeutics are massive protein complexes (~150,000 Daltons) featuring complex tertiary and quaternary folding.
• Inherent Micro-Heterogeneity: Living cells naturally introduce minor, non-critical variations (such as post-translational glycosylation patterns) during production. Regulatory frameworks ensure these minor differences do not alter safety or therapeutic activity.

The Reverse-Engineering Paradigm

Developing a biosimilar requires a “reverse-engineering” approach to match the reference drug’s critical quality attributes (CQAs):

The Totality-of-the-Evidence Approach

Regulatory approval for a biosimilar relies on demonstrating “totality of the evidence.” Unlike original biologics—which rely primarily on large-scale clinical trials to establish efficacy—biosimilar approval focuses heavily on analytical and functional characterization:

Extrapolation and Interchangeability

Two key regulatory concepts govern the clinical application of biosimilars:

• Extrapolation: If biosimilarity is scientifically proven for one medical condition, regulatory agencies can approve the biosimilar for other indications held by the reference drug without repeating clinical trials for every single indication.
• Interchangeability: An interchangeability designation indicates that a biosimilar can be substituted for the reference product at the pharmacy level without requiring intervention from the prescribing healthcare provider, depending on regional regulatory frameworks.

Scientific Comparison Summary

Final Thoughts

Biosimilars are engineered to meet strict standards of structural similarity, functional equivalence, and clinical safety. By providing comparable therapeutic outcomes at lower costs, biosimilars expand access to life-changing biological therapies worldwide.